Amedeo Smart

Free Medical Literature Service

 

Amedeo

Schizophrenia
  Free Subscription

Articles published in
Neuropsychopharmacology
    November 2025
  1. TARUMI R, Honda S, Cassidy C, Etani T, et al
    Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia.
    Neuropsychopharmacology. 2025 Nov 7. doi: 10.1038/s41386-025-02275.
    >> Share

    October 2025
  2. O'BRIEN KJ, Huque ZM, Pike MR, Smith EC, et al
    Synergistic pathways to psychosis: understanding developmental risk and resilience factors.
    Neuropsychopharmacology. 2025 Oct 10. doi: 10.1038/s41386-025-02261.
    >> Share

  3. CHATTERJEE S, Soria M, Norville ZC, Thompson KR, et al
    Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
    Neuropsychopharmacology. 2025 Oct 4. doi: 10.1038/s41386-025-02256.
    >> Share

    September 2025
  4. GARCIA-CERRO S, Gomez-Garrido A, Soria FN, Loucera C, et al
    Clozapine induces perineuronal net remodeling in a developmental mouse model exhibiting schizophrenia-relevant phenotypes.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02210.
    >> Share

  5. GIRGIS RR, de la Fuente-Sandoval C, Lewis-Fernandez R, Reyes-Madrigal F, et al
    Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02251.
    >> Share

  6. HERMS EN, Wisner KM
    Moving from isolation to integration: a Bayesian multisensory perspective of interoception and psychosis.
    Neuropsychopharmacology. 2025 Sep 24. doi: 10.1038/s41386-025-02250.
    >> Share

  7. HOLMES DR
    From psychosis to creativity: a lived experience perspective on serious mental illness symptoms.
    Neuropsychopharmacology. 2025 Sep 10. doi: 10.1038/s41386-025-02212.
    >> Share

    August 2025
  8. BERSHAD AK
    For those with schizophrenia, does cannabidiol make cannabis use safer?
    Neuropsychopharmacology. 2025 Aug 26. doi: 10.1038/s41386-025-02199.
    >> Share

  9. ANKEETA A, Tripathi A, Pillai B, Ma Y, et al
    Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia.
    Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02204.
    >> Share

  10. KU BS, Young JW
    Social environment as a determinant of mismatch negativity in early psychosis.
    Neuropsychopharmacology. 2025 Aug 19. doi: 10.1038/s41386-025-02195.
    >> Share

  11. FERLAND JN, Di Forti M
    Rewired realities: novel insights into the neurobiology of cannabis use disorder and psychosis.
    Neuropsychopharmacology. 2025 Aug 6. doi: 10.1038/s41386-025-02189.
    >> Share

  12. ULIANA DL, Walsh RA, Fabris D, Grace AA, et al
    Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model.
    Neuropsychopharmacology. 2025 Aug 5. doi: 10.1038/s41386-025-02188.
    >> Share

    July 2025
  13. CHESNEY E, Oliver D, Sarma A, Lamper AD, et al
    Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.
    Neuropsychopharmacology. 2025 Jul 24. doi: 10.1038/s41386-025-02175.
    >> Share

  14. KAWATAKE-KUNO A, Leventhal MB, Morishita H
    Impact of early social isolation on social circuits and behavior: relevance to schizophrenia.
    Neuropsychopharmacology. 2025 Jul 4. doi: 10.1038/s41386-025-02156.
    >> Share

    May 2025
  15. HUANG H, Wang X, Qin X, Xu R, et al
    Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis.
    Neuropsychopharmacology. 2025 May 28. doi: 10.1038/s41386-025-02135.
    >> Share

  16. KING VL, Hellemann G, Lahti AC, Defenderfer M, et al
    Cortical myelin mapping in antipsychotic medication-naive, first-episode psychosis patients.
    Neuropsychopharmacology. 2025 May 23. doi: 10.1038/s41386-025-02137.
    >> Share

    April 2025
  17. GOLDSMITH DR, Ning CS, Strauss GP, Gross RE, et al
    Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia.
    Neuropsychopharmacology. 2025 Apr 24. doi: 10.1038/s41386-025-02114.
    >> Share

  18. KU BS, Hamilton H, Yuan Q, Parker DA, et al
    Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons.
    Neuropsychopharmacology. 2025 Apr 2. doi: 10.1038/s41386-025-02093.
    >> Share

    March 2025
  19. DHAMALA E, Rubio JM
    Persistent brain network signatures in psychosis: implications for diagnosis, prognosis, and treatment.
    Neuropsychopharmacology. 2025 Mar 5. doi: 10.1038/s41386-025-02079.
    >> Share

    February 2025
  20. DYBOWSKI FP, Scott DS, Tamminga CA
    Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02077.
    >> Share

  21. FOSTER ML, Ye J, Powers AR, Dvornek NC, et al
    Connectome-based predictive modeling of early and chronic psychosis symptoms.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02064.
    >> Share

  22. SAMSOM JN, Xu M, Avila A, Daskalakis AA, et al
    Protein interacting with C-kinase 1 (PICK1) regulates synaptic function and reversal learning in a mouse model for schizophrenia.
    Neuropsychopharmacology. 2025 Feb 22. doi: 10.1038/s41386-025-02072.
    >> Share

    November 2024
  23. ZHANG W, Wang L, Wu X, Yao L, et al
    Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia.
    Neuropsychopharmacology. 2024 Nov 6. doi: 10.1038/s41386-024-02021.
    >> Share

    September 2024
  24. BRAKATSELOS C, Polissidis A, Ntoulas G, Asprogerakas MZ, et al
    Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
    Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01977.
    >> Share

    August 2024
  25. SLIFSTEIN M, Qu W, Gil R, Weinstein JJ, et al
    Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.
    Neuropsychopharmacology. 2024 Aug 31. doi: 10.1038/s41386-024-01975.
    >> Share

    July 2024
  26. ABRAM SV, Hua JPY
    Pons connectivity correlates with neurophysiological and clinical signatures of predictive coding in psychosis.
    Neuropsychopharmacology. 2024 Jul 22. doi: 10.1038/s41386-024-01919.
    >> Share

  27. SMUCNY J, Carter CS
    Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy.
    Neuropsychopharmacology. 2024 Jul 18. doi: 10.1038/s41386-024-01932.
    >> Share

    June 2024
  28. JOHNSON EC, Austin-Zimmerman I, Thorpe HHA, Levey DF, et al
    Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 21. doi: 10.1038/s41386-024-01886.
    >> Share

  29. CHENOWETH MJ
    Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 11. doi: 10.1038/s41386-024-01898.
    >> Share

  30. KOCH E, Kampe A, Alver M, Siguretharson S, et al
    Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study.
    Neuropsychopharmacology. 2024;49:1113-1119.
    >> Share

    May 2024
  31. PISANU C, Congiu D, Meloni A, Paribello P, et al
    Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.
    Neuropsychopharmacology. 2024;49:1033-1041.
    >> Share

    April 2024
  32. LIVINGSTON NR, Kiemes A, Devenyi GA, Knight S, et al
    Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2024 Apr 24. doi: 10.1038/s41386-024-01864.
    >> Share

    March 2024
  33. SCHOONOVER KE, Dienel SJ, Holly Bazmi H, Enwright JF 3rd, et al
    Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia.
    Neuropsychopharmacology. 2024 Mar 28. doi: 10.1038/s41386-024-01854.
    >> Share

  34. HUANG AS, Kang K, Vandekar S, Rogers BP, et al
    Lifespan development of thalamic nuclei and characterizing thalamic nuclei abnormalities in schizophrenia using normative modeling.
    Neuropsychopharmacology. 2024 Mar 13. doi: 10.1038/s41386-024-01837.
    >> Share

  35. SEITZ-HOLLAND J, Aleman-Gomez Y, Cho KIK, Pasternak O, et al
    Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
    Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814.
    >> Share

    February 2024
  36. CABRERA-MENDOZA B, Aydin N, Fries GR, Docherty AR, et al
    Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach.
    Neuropsychopharmacology. 2024 Feb 23. doi: 10.1038/s41386-024-01833.
    >> Share

  37. TRUONG TTT, Liu ZSJ, Panizzutti B, Kim JH, et al
    Network-based drug repurposing for schizophrenia.
    Neuropsychopharmacology. 2024 Feb 6. doi: 10.1038/s41386-024-01805.
    >> Share

    January 2024
  38. PAUL SM, Potter WZ
    Finding new and better treatments for psychiatric disorders.
    Neuropsychopharmacology. 2024;49:3-9.
    >> Share

  39. HANSON JE, Yuan H, Perszyk RE, Banke TG, et al
    Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
    Neuropsychopharmacology. 2024;49:51-66.
    >> Share

    December 2023
  40. ARIME Y, Saitoh Y, Ishikawa M, Kamiyoshihara C, et al
    Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia.
    Neuropsychopharmacology. 2023 Dec 4. doi: 10.1038/s41386-023-01769.
    >> Share

    October 2023
  41. WANG DM, Chen DC, Xiu MH, Wang L, et al
    A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
    Neuropsychopharmacology. 2023 Oct 30. doi: 10.1038/s41386-023-01760.
    >> Share

  42. ROESKE MJ, McHugo M, Rogers B, Armstrong K, et al
    Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Neuropsychopharmacology. 2023 Oct 13. doi: 10.1038/s41386-023-01730.
    >> Share

    September 2023
  43. FAN L, Liang L, Wang Y, Ma X, et al
    Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
    Neuropsychopharmacology. 2023 Sep 26. doi: 10.1038/s41386-023-01741.
    >> Share

  44. ZHOU DY, Su X, Wu Y, Yang Y, et al
    Decreased CNNM2 expression in prefrontal cortex affects sensorimotor gating function, cognition, dendritic spine morphogenesis and risk of schizophrenia.
    Neuropsychopharmacology. 2023 Sep 15. doi: 10.1038/s41386-023-01732.
    >> Share

  45. RABIN RA, Palaniyappan L
    Brain health in ethnically minority youth at risk for psychosis.
    Neuropsychopharmacology. 2023 Sep 4. doi: 10.1038/s41386-023-01719.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016